AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2978461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulization treatment with ipratropium bromide 30 minutes after terbutaline
Number of subjects: 77
Study 31391011 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (100 mg weekly intramuscular injections for 7 weeks)
Number of subjects: 11
Study 31391011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 27677733 — intervention group
Group type: EXPERIMENTAL
Intervention: VF biofeedback only
Number of subjects: 30
Study 27677733 — intervention group
Group type: COMPARATOR
Intervention: ssEMG biofeedback only
Number of subjects: 30
Study 27677733 — intervention group
Group type: COMPARATOR
Intervention: Mixed biofeedback (VF for demonstration, ssEMG for training)
Number of subjects: 30
Study 25287787 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline dispositional mindfulness
Number of subjects: 0
Study 25287787 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline dispositional mindfulness
Number of subjects: 0
Study 25287787 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in waking cortisol
Number of subjects: 0
Study 23247928 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric, protein-, and mineral-enriched postdischarge formula (PDF), n=52
Number of subjects: 93
Study 23247928 — intervention group
Group type: COMPARATOR
Intervention: Standard term formula (TF), n=41
Number of subjects: 93
Study 23247928 — intervention group
Group type: COMPARATOR
Intervention: Human milk (HM), n=46
Number of subjects: 93
Study 21562190 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency MEG phase information during speech perception
Number of subjects: 0
Study 21562190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of frequency bands in classifier results
Number of subjects: 0
Study 18852963 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct and indirect intervention (TG)
Number of subjects: 11
Study 18852963 — intervention group
Group type: COMPARATOR
Intervention: Indirect intervention exclusively (OG)
Number of subjects: 11
Study 17139244 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with capecitabine
Number of subjects: 0
Study 17139244 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with paclitaxel
Number of subjects: 0
Study 17139244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0
Study 17139244 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with antiangiogenic agents
Number of subjects: 0
Study 14978782 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (10 sessions of 10-Hz rTMS to the left dorsolateral prefrontal cortex at 110% motor threshold)
Number of subjects: 15
Study 14978782 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 15
Study 14978782 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 15
Study 11252011 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental therapy
Number of subjects: 0
Study 11252011 — intervention group
Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 0
Study 9425767 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Gide
Number of subjects: 25
Study 9425767 — intervention group
Group type: COMPARATOR
Intervention: Gore-Tex
Number of subjects: 25
Study 7684440 — intervention group
Group type: EXPERIMENTAL
Intervention: State definitions for at-risk children (composite)
Number of subjects: 985
Study 7684440 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual risk factors (e.g., hypothyroidism)
Number of subjects: 985
Study 7684440 — intervention group
Group type: EXPERIMENTAL
Intervention: Commonly identified risk factors
Number of subjects: 985
Study 3120486 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil and thiopentone induction, 66% N2O maintenance
Number of subjects: 100
Study 3120486 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil and midazolam sedation prior to isoflurane and N2O induction and maintenance
Number of subjects: 100
Study 3120486 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam and alfentanil induction; oxygen/air, placebo reversal
Number of subjects: 100
Study 3120486 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam and alfentanil induction, oxygen/air, flumazenil reversal
Number of subjects: 100
Study 31859211 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stop myocardial computed tomography perfusion (CTP)
Number of subjects: 442
Study 31859211 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary CT angiography (CCTA)
Number of subjects: 442
Study 31078564 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation + Mastery (n=58)
Number of subjects: 119
Study 31078564 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation (n=61)
Number of subjects: 119
Study 31078564 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 119
Study 28101567 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm crank ergometer training
Number of subjects: 49
Study 28101567 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 49
Study 25287262 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiautomatic volumetric software with a threshold of -300 HU
Number of subjects: 115
Study 25287262 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiautomatic volumetric measurements at a threshold of -130 HU
Number of subjects: 115
Study 24057294 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/d (increased to 45 mg/d after 1 month)
Number of subjects: 156
Study 24057294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 24057294 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 156
Study 21765448 — intervention group
Group type: EXPERIMENTAL
Intervention: iptakalim (5 or 10 mg/d, po) for 8 weeks
Number of subjects: 162
Study 21765448 — intervention group
Group type: EXPERIMENTAL
Intervention: TT genotype for A190A polymorphism
Number of subjects: 162
Study 19807917 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus dalteparin (5000 IU daily subcutaneous injection for 24 weeks)
Number of subjects: 2200
Study 16677149 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha 2b plus lamivudine
Number of subjects: 26
Study 16677149 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha 2b
Number of subjects: 26
Study 14667697 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronouns with infrequent antecedents
Number of subjects: 0
Study 14667697 — intervention group
Group type: COMPARATOR
Intervention: Pronouns with frequent antecedents
Number of subjects: 0
Study 11594714 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling service model for couples participating in ART
Number of subjects: 60
Study 11594714 — intervention group
Group type: COMPARATOR
Intervention: Routine procedures currently included in ART (Control group)
Number of subjects: 60
Study 11189315 — intervention group
Group type: EXPERIMENTAL
Intervention: Gu Chi Gao
Number of subjects: 24
Study 11189315 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 24
Study 7955998 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 20
Study 7955998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3150952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (2 g i.v. at induction, two additional doses every 12 h)
Number of subjects: 65
Study 3150952 — intervention group
Group type: COMPARATOR
Intervention: Clindamicin (600 mg i.v. at induction) plus Aztreonam (1 g i.v., two additional doses every 8 h)
Number of subjects: 65
Study 3150952 — intervention group
Group type: COMPARATOR
Intervention: Clindamicin plus Aztreonam
Number of subjects: 65
Study 3150952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 65
Study 30616868 — intervention group
Group type: EXPERIMENTAL
Intervention: STN+SNr‐DBS
Number of subjects: 15
Study 30616868 — intervention group
Group type: COMPARATOR
Intervention: STN‐DBS
Number of subjects: 15
Study 28527156 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 60
Study 28527156 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic-strength exercise
Number of subjects: 60
Study 28527156 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 25771714 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumescent suction curettage (TSC)
Number of subjects: 30
Study 24704090 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clobetasol propionate 0.05%
Number of subjects: 58
Study 24704090 — intervention group
Group type: COMPARATOR
Intervention: Topical tacrolimus 0.1%
Number of subjects: 58
Study 23000693 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised respiratory physiotherapy (positioning, thoracic vibration, thoracic compression, positive expiratory pressure, breathing exercises, forced exhalation with the glottis open or 'huffing') three times daily.
Number of subjects: 72
Study 23000693 — intervention group
Group type: COMPARATOR
Intervention: Non-mandatory request to breathe deeply, expectorate sputum, and maintain a lateral body position once a day.
Number of subjects: 72
Study 23000693 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-mandatory request)
Number of subjects: 72
Study 23000693 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (chest physiotherapy)
Number of subjects: 72
Study 19647670 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction method based on waist girth applied to dual-energy X-ray absorptiometry output
Number of subjects: 0
Study 17596730 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 22
Study 17596730 — intervention group
Group type: COMPARATOR
Intervention: Patient-Triggered Ventilation (PTV)
Number of subjects: 22
Study 15052871 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 70
Study 14612206 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 2 g/day plus Vitamin E 400 IU/day (Group B)
Number of subjects: 43
Study 14612206 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 2 g/day plus Vitamin E 800 IU/day (Group C)
Number of subjects: 43
Study 14612206 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C 2 g/day (Group A)
Number of subjects: 43
Study 14612206 — intervention group
Group type: COMPARATOR
Intervention: No antioxidant treatment (Group D)
Number of subjects: 43
Study 9768015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7662437 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing diagnosis assessment by student and registered nurses
Number of subjects: 100
Study 2502441 — intervention group
Group type: EXPERIMENTAL
Intervention: Short‐Buserelin‐gonadotropin regimen
Number of subjects: 262
Study 2502441 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)/hMG regimen
Number of subjects: 262
Study 332191 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincamine (60 mg p.o. daily for 6 weeks)
Number of subjects: 30
Study 332191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31194946 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose extracorporeal shockwave therapy (ESWT) for 4 weeks
Number of subjects: 63
Study 31194946 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham shockwave therapy)
Number of subjects: 63
Study 31194946 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose extracorporeal shockwave therapy (ESWT)
Number of subjects: 63
Study 28167188 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF stretching
Number of subjects: 65
Study 28167188 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 65
Study 28167188 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 65
Study 28167188 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study 25295834 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist led patient self-testing (PST)
Number of subjects: 0
Study 25295834 — intervention group
Group type: COMPARATOR
Intervention: Routine care (management in a hospital based anti-coagulation clinic)
Number of subjects: 0
Study 23421968 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/Salmeterol combination (FSC)
Number of subjects: 15
Study 23421968 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 15
Study 21744732 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol+remifentanil
Number of subjects: 30
Study 21744732 — intervention group
Group type: COMPARATOR
Intervention: propofol+alfentanil
Number of subjects: 30
Study 19347118 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal antibiotic injection, associated with topical and oral antibiotics (Group 1, n=24)
Number of subjects: 35
Study 19347118 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy and silicone oil injection with intravitreal antibiotic injection (Group 2, n=11)
Number of subjects: 35
Study 16920897 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine (C(max) in young men: 338 ng/mL; elderly men: 310 ng/mL)
Number of subjects: 0
Study 16920897 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine (AUC in young men: 2040 ng x h/mL; elderly men: 2280 ng x h/mL)
Number of subjects: 0
Study 16920897 — intervention group
Group type: COMPARATOR
Intervention: Dapoxetine with food (C(max) in fed state: 398 ng/mL; fasted state: 443 ng/mL)
Number of subjects: 0
Study 16920897 — intervention group
Group type: COMPARATOR
Intervention: Dapoxetine with food (AUC)
Number of subjects: 0
Study 15228505 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipperport
Number of subjects: 20
Study 15228505 — intervention group
Group type: EXPERIMENTAL
Intervention: Jordy
Number of subjects: 20
Study 15228505 — intervention group
Group type: COMPARATOR
Intervention: HMDs (Jordy, Flipperport, Maxport, NuVision)
Number of subjects: 20
Study 15228505 — intervention group
Group type: COMPARATOR
Intervention: Conventional optical aids (LVAs)
Number of subjects: 20
Study 11354238 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine (50-450 mg, mean 207 +/- 125 mg/day)
Number of subjects: 108
Study 11354238 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 108
Study 9244025 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at the PC6 point
Number of subjects: 81
Study 9244025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 8489310 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MM) in maintenance immunosuppression regimen
Number of subjects: 47
Study 8489310 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MM) for reversing refractory renal allograft rejection
Number of subjects: 47
Study 3514949 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial thickness and texture assessment during IVF induction
Number of subjects: 320
Study 3514949 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial thickness measurement
Number of subjects: 320
Study 29106814 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-ingredient nutritional supplement (SUPP)
Number of subjects: 0
Study 29106814 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-based control (CON)
Number of subjects: 0
Study 27088998 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomized lidocaine (4% lidocaine, 2 mg/kg) administered using a mucosal atomization device
Number of subjects: 20
Study 27088998 — intervention group
Group type: COMPARATOR
Intervention: Nonatomized lidocaine (4% lidocaine, 2 mg/kg) administered using a traditional spray tube
Number of subjects: 20
Study 27088998 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomized lidocaine
Number of subjects: 20
Study 27088998 — intervention group
Group type: COMPARATOR
Intervention: Nonatomized lidocaine
Number of subjects: 20
Study 27088998 — intervention group
Group type: EXPERIMENTAL
Intervention: Both atomized and nonatomized lidocaine
Number of subjects: 20
Study 25465686 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel sealant (Resure)
Number of subjects: 500
Study 25465686 — intervention group
Group type: COMPARATOR
Intervention: Nylon suture
Number of subjects: 500
Study 23070488 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 hours in bed (sleep restriction)
Number of subjects: 7
Study 23070488 — intervention group
Group type: COMPARATOR
Intervention: 8.5 hours in bed (normal sleep)
Number of subjects: 7
Study 16056048 — intervention group
Group type: EXPERIMENTAL
Intervention: Interax ISA mobile platform total knee arthroplasties
Number of subjects: 35
Study 12002728 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-allergic mattress encasings
Number of subjects: 27
Study 12002728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 9467442 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTek (Vifilcon A) therapeutic soft contact lens
Number of subjects: 47
Study 9467442 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard postoperative care)
Number of subjects: 47
Study 8586079 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger probing allowed for normal subjects
Number of subjects: 26
Study 8586079 — intervention group
Group type: COMPARATOR
Intervention: Finger probing allowed for CTS subjects
Number of subjects: 26
Study 8586079 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger probing not allowed for normal subjects
Number of subjects: 26
Study 8586079 — intervention group
Group type: COMPARATOR
Intervention: Finger probing not allowed for CTS subjects
Number of subjects: 26
Study 2186274 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (display of charges for tests)
Number of subjects: 121
Study 2186274 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (scheduled visits)
Number of subjects: 121
Study 2186274 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (unscheduled visits)
Number of subjects: 121
Study 2186274 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (post-intervention)
Number of subjects: 121
Study 2186274 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 707334 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acids and alpha-keto acid analogues
Number of subjects: 0
Study 707334 — intervention group
Group type: EXPERIMENTAL
Intervention: Keto acid analogue therapy
Number of subjects: 0
Study 707334 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-hydroxy acid analogues
Number of subjects: 0
Study 707334 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet
Number of subjects: 0
Study 31984652 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 28
Study 31984652 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 28
Study 31984652 — intervention group
Group type: EXPERIMENTAL
Intervention: All assessed survivors
Number of subjects: 28
Study 30841823 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA (6 g/day) with vitamin B6 (40 mg/day)
Number of subjects: 42
Study 30841823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 28169153 — intervention group
Group type: EXPERIMENTAL
Intervention: WT alone (FSG)
Number of subjects: 30
Study 28169153 — intervention group
Group type: EXPERIMENTAL
Intervention: WT combined to jump and sprint exercises (COM)
Number of subjects: 30
Study 28169153 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study 26152131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg infusions administered every 8 or 12 hours (q8h or q12h)
Number of subjects: 67
Study 24088189 — intervention group
Group type: EXPERIMENTAL
Intervention: Boswellia Serrata (BS) capsules for 6 weeks
Number of subjects: 38
Study 24088189 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 38
Study 21119150 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment adherence therapy (TAT)
Number of subjects: 109
Study 21119150 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 109
Study 18805249 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week CBSM group intervention (n=21)
Number of subjects: 39
Study 18805249 — intervention group
Group type: COMPARATOR
Intervention: 1-day CBSM workshop (n=18)
Number of subjects: 39
Study 17079573 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of erythropoietin, iron, folate, and vitamin B12
Number of subjects: 0
Study 17079573 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12941710 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (10-15 mg sibutramine daily, low-calorie diets using meal replacement products for 1 week every 2 months, and daily use of meal replacement product and snack bars)
Number of subjects: 0
Study 12941710 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study 12941710 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 12941710 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 10986106 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated drink consumed after 12 h caffeine deprivation
Number of subjects: 36
Study 10986106 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-deprived group who no longer received caffeine
Number of subjects: 36
Study 10986106 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-deprived state groups
Number of subjects: 36
Study 8742095 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide in combination with LHRH analogs
Number of subjects: 0
Study 8742095 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 0
Study 8742095 — intervention group
Group type: COMPARATOR
Intervention: Flutamide in combination with LHRH analogs
Number of subjects: 0
Study 1418054 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg/d for 3 days, then 2 x 10 mg/d for 39 days)
Number of subjects: 88
Study 1418054 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 88